A recent clinical trial has revealed that a widely available nasal spray used for allergies could significantly reduce the risk of COVID‑19 infection.
The spray, which contains the antihistamine azelastine, was used three times daily over eight weeks and was shown to cut infection rates by about two-thirds compared to a placebo. Participants also experienced fewer symptomatic cases, delayed onset of illness, and even a reduction in common colds.
The double‑blind trial involved around 450 healthy, mostly vaccinated adults. Only 2.2% of those using azelastine contracted COVID‑19, compared to 6.7% in the placebo group.
The spray’s safety profile remained consistent with known side effects, such as mild dryness or a bitter taste, and no serious issues were reported.
Although the results are promising, the researchers emphasized that the study was limited in scale and location, and involved primarily young, healthy participants. Larger, more diverse trials are needed before widespread recommendations can be made.
Still, in a world where COVID‑19 variants continue to emerge and vaccine coverage varies, this simple, over-the-counter spray could offer an affordable, accessible extra layer of protection—especially in crowded or high-risk settings.